Trials / Unknown
UnknownNCT04642937
Study of CD200 Activation Receptor Ligand (CD200AR-L) and Allogeneic Tumor Lysate Vaccine Immunotherapy for Recurrent Glioblastoma
- Status
- Unknown
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 24 (estimated)
- Sponsor
- OX2 Therapeutics · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a single-center, open-label, dose-range finding Phase I study of hP1A8, a new adjuvant CD200 activation receptor ligand (CD200AR-L), in combination with imiquimod and the GBM6-AD vaccine to treat recurrent glioblastoma (GBM) in adults.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Treatment with hP1A8 | Treatment with hP1A8 |
Timeline
- Start date
- 2020-12-01
- Primary completion
- 2023-11-01
- Completion
- 2024-11-01
- First posted
- 2020-11-24
- Last updated
- 2023-01-27
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04642937. Inclusion in this directory is not an endorsement.